As the disease progresses in the APOE 4 carriers, metabolites associated with reducing atherosclerosis and the TCA cycle and oxidative phosphorylation appeared to correlate with (and perhaps to drive) the differences between early- and late-stage AD. This evidence concerns the gene APOE and Alzheimer disease.